PPC
TEVA icon

Park Place Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Park Place Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.4K Hold
543
– – ﹤0.01% 700
2026
Q1 		$16.4K Buy
543
+56
+11% +$1.8K ﹤0.01% 517
2025
Q4 		$15.2K Hold
487
– – ﹤0.01% 497
2025
Q3 		$9.84K Sell
487
-196
-29% -$3.44K ﹤0.01% 554
2025
Q2 		$11.4K Hold
683
– – ﹤0.01% 565
2025
Q1 		$10.5K Hold
683
– – ﹤0.01% 573
2024
Q4 		$15.1K Buy
683
+217
+47% +$3.95K ﹤0.01% 519
2024
Q3 		$8.4K Buy
466
+395
+556% +$6.91K ﹤0.01% 640
2024
Q2 		$1.15K Buy
+71
New +$1.09K ﹤0.01% 823

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Park Place Capital's TEVA Position: Q2 2026 in Review

Park Place Capital held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 543 shares worth $18.4K. The position accounts for ﹤0.01% of the portfolio, ranked #700.

Park Place Capital first reported a position in TEVA in Q2 2024 and has held it in 9 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Park Place Capital held 543 shares of Teva Pharmaceuticals worth $18.4K as of Q2 2026.
  • Park Place Capital left its Teva Pharmaceuticals share count unchanged in Q2 2026.
  • Teva Pharmaceuticals made up ﹤0.01% of Park Place Capital's portfolio in Q2 2026, its #700 holding.
  • Park Place Capital first reported a position in Teva Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Park Place Capital's 13F filing for Q2 2026, filed 14 Aug 2026.